Welcome to our dedicated page for NMTR news (Ticker: NMTR), a resource for investors and traders seeking the latest updates and insights on NMTR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMTR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMTR's position in the market.
9 Meters Biopharma (NASDAQ:NMTR) has appointed Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications. Liu brings extensive experience in the rare disease sector, expected to aid the company’s transition to commercial operations, particularly for its candidates targeting celiac disease and short bowel syndrome. Medwar's expertise in investor relations will enhance communication with stakeholders as the company advances its GI-focused pipeline, including promising products like vurolenatide and larazotide.
9 Meters Biopharma (NASDAQ:NMTR) announced an unrestricted educational grant to Carol Rees Parrish, M.S., RDN, to develop the SBSCurbside educational website, aiding clinicians in treating Short Bowel Syndrome (SBS). SBS causes severe nutrient malabsorption, challenging management for clinicians. The grant aims to enhance education for healthcare providers, ensuring better patient care. Patrick H. Griffin, M.D. emphasized the importance of increased knowledge among physicians. The program is set to launch in January 2022.
9 Meters Biopharma reported a net loss of approximately $13.5 million for Q3 2021, or $0.05 per share, compared to a $8.3 million loss in Q3 2020. The company holds $53.6 million in cash, projected to fund operations into 2023. Key updates include the completion of Phase 2 study enrollment for vurolenatide expected by year-end and interim analysis of larazotide in Q2 2022. The appointment of Samantha Ventimiglia to the Board is also noted. The company remains focused on development milestones for its novel treatments for digestive diseases.
9 Meters Biopharma (NASDAQ:NMTR) announced a collaboration with Gustave Roussy to investigate NM-102, a gut-selective peptide. This collaboration builds on previous preclinical findings suggesting NM-102 enhances the efficacy of immune checkpoint inhibitors (ICIs) in treating cancer. The company is pursuing an IND-enabling pathway, with indication selection expected in 2022. Additionally, NM-102 has received a recently issued composition of matter patent, further solidifying its potential as a novel therapy to improve ICI responses.
9 Meters Biopharma (NASDAQ: NMTR) will present at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021. CEO John Temperato is scheduled to speak from 10:00 to 10:35 a.m. GMT, discussing the company's innovative solutions for rare digestive diseases. Investors can engage in one-on-one meetings in person on November 16-17 or virtually on November 18-19. Key products include vurolenatide for short bowel syndrome and larazotide for celiac disease. A replay of the presentation will be available for 90 days.
9 Meters Biopharma (NASDAQ:NMTR) presented pharmacokinetic data for vurolenatide, a long-acting GLP-1 agonist for short bowel syndrome (SBS), at the ACG 2021 Annual Scientific Meeting. The data indicate twice-monthly dosing is adequate to sustain therapeutic levels, offering a less burdensome treatment option for patients. Top-line results from the ongoing Phase 2 VIBRANT trial are expected by year-end. The company aims to improve gastric motility and reduce diarrhea for SBS patients. Vurolenatide is currently in a significant Phase 2 trial following positive prior results.
9 Meters Biopharma (NASDAQ:NMTR) will present a poster on its therapeutic candidate vurolenatide for short bowel syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting. The event takes place from October 22-27, 2021 in Las Vegas, Nevada. The poster presentation, led by Patrick H. Griffin, M.D., will occur on October 26, with the poster on display from 10:30 a.m. to 4 p.m. PT. The company will also exhibit at booth 843 during the meeting.
9 Meters Biopharma (NASDAQ:NMTR) announced the appointment of Samantha Ventimiglia to its Board of Directors on October 4, 2021. Ventimiglia, currently Senior VP of U.S. Public Affairs at Vertex Pharmaceuticals, brings extensive experience in healthcare policy and government relations. Her role is expected to enhance the company's growth as it transitions from clinical to commercial stages, particularly in advancing treatments for celiac disease and short bowel syndrome. The company is focused on pioneering treatments for rare digestive diseases.
9 Meters Biopharma (NASDAQ:NMTR) announces CEO John Temperato will present at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. The live presentation is scheduled for September 28, 2021, at 4:40 - 5:10 p.m. (ET), with a replay available for 90 days. Investors can join via webcast and arrange one-on-one meetings with representatives. 9 Meters focuses on developing innovative treatments for rare digestive diseases, including vurolenatide for short bowel syndrome and larazotide for celiac disease.
FAQ
What is the market cap of NMTR (NMTR)?
